Pushing the Boundaries of MS-Based Clinical Proteomics: Taking Biology Beyond ID Numbers
Join leading researchers as they demonstrate how ZT Scan DIA is transforming clinical proteomics workflows and accelerating the path from biomarker discovery to clinical implementation.
Mass spectrometry (MS)-based proteomics can identify and quantify thousands of potential biomarker proteins from complex biospecimens, yet a critical challenge remains: translating promising research discoveries into FDA-validated diagnostic metrics. The gap between discovery and clinical application often lies in scaling workflows that maintain high specificity and sensitivity across large, diverse patient cohorts.
Enter ZT Scan DIA – a breakthrough data-independent acquisition strategy that combines DDA, DIA, and MRM approaches. Using scanning quadrupole technology paired with a Zeno trap-enabled QTOF system, ZT Scan DIA delivers higher duty cycles at faster acquisition speeds, resulting in improved spectral quality and more accurate precursor association.
This innovative approach aims to bridge the discovery-to-clinic gap, enabling the robust proteomic pipelines essential for advancing precision medicine.
Attend to gain free access to "Revolutionizing Biomedical Research with a Novel DIA Strategy," which includes practical implementation guidelines.
Key learnings:
Discover how to overcome the discovery-to-clinic translation challenge in proteomics, learn practical implementation strategies for ZT Scan DIA technology, and understand how to scale high-quality biomarker workflows for large patient cohorts while maintaining FDA validation standards.
Who Should Attend:
- Proteomics Researchers
- Clinical Laboratory Directors
- Biomarker Discovery Scientists
- Translational Researchers
- Regulatory Affairs Professionals
- Pharmaceutical R&D Teams working on precision medicine initiatives and clinical diagnostic development.
Presenter: Ludwig Roman Sinn (Scientist, Post-Doctorate of Ralser and Demichev Labs, Charité – Universitätsmedizin Berlin)
Ludwig R. Sinn studied Biochemistry at MLU Halle-Wittenberg, completing his doctorate at Technische Universität Berlin under Juri Rappsilber, where he focused on crosslinking and mass spectrometry for systems structural biology. In 2022, he joined the labs of Vadim Demichev and Markus Ralser as a postdoctoral researcher, developing novel proteomics methods aimed at increasing throughput, sensitivity, and versatility to enhance our understanding of fungal drug tolerance and human health (e.g., glycoproteomics, clinical, and microbial proteomics).
Presenter: Mohammadreza Dorvash (PhD Candidate, Purcell Lab, Monash University)
Reza Dorvash is a PhD candidate at Monash University, working under supervision of professor Anthony Purcell. Reza specializes in antigen discovery in Pancreatic Cancer using LC-MS/MS. Utilizing advanced techniques like ZenoSWATH and ZTScan DIA on the SCIEX ZenoTOF 7600 platform, he investigates the Pancreatic Cancer HLA-peptidome (T-cell targets) isolated from minimal input materials (one million cells). His research focuses on HLA-peptides derived from tumor-associated antigens and endogenous retroviruses, as well as studying phosphorylated HLA-peptides using EAD and EAD+CID methods.
